GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XTER:NOV) » Definitions » Cyclically Adjusted Price-to-FCF

Novo Nordisk AS (XTER:NOV) Cyclically Adjusted Price-to-FCF : 42.68 (As of Jun. 02, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Novo Nordisk AS Cyclically Adjusted Price-to-FCF?

As of today (2025-06-02), Novo Nordisk AS's current share price is €62.32. Novo Nordisk AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €1.46. Novo Nordisk AS's Cyclically Adjusted Price-to-FCF for today is 42.68.

The historical rank and industry rank for Novo Nordisk AS's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XTER:NOV' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 27.84   Med: 42.84   Max: 104.1
Current: 41.76

During the past years, Novo Nordisk AS's highest Cyclically Adjusted Price-to-FCF was 104.10. The lowest was 27.84. And the median was 42.84.

XTER:NOV's Cyclically Adjusted Price-to-FCF is ranked worse than
61.35% of 326 companies
in the Drug Manufacturers industry
Industry Median: 31.13 vs XTER:NOV: 41.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novo Nordisk AS's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €0.302. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.46 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cyclically Adjusted Price-to-FCF Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.50 54.67 56.11 73.65 58.89

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.21 97.23 72.67 58.89 43.24

Competitive Comparison of Novo Nordisk AS's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novo Nordisk AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novo Nordisk AS's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=62.32/1.46
=42.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novo Nordisk AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.302/120.2000*120.2000
=0.302

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.281 100.300 0.337
201509 0.281 100.200 0.337
201512 0.183 99.800 0.220
201603 0.166 100.200 0.199
201606 0.337 100.600 0.403
201609 0.334 100.200 0.401
201612 0.224 100.300 0.268
201703 0.279 101.200 0.331
201706 0.230 101.200 0.273
201709 0.297 101.800 0.351
201712 0.076 101.300 0.090
201803 0.188 101.700 0.222
201806 0.365 102.300 0.429
201809 0.241 102.400 0.283
201812 0.096 102.100 0.113
201903 0.192 102.900 0.224
201906 0.344 102.900 0.402
201909 0.402 102.900 0.470
201912 0.062 102.900 0.072
202003 0.235 103.300 0.273
202006 0.655 103.200 0.763
202009 0.329 103.500 0.382
202012 -0.368 103.400 -0.428
202103 0.283 104.300 0.326
202106 0.681 105.000 0.780
202109 0.580 105.800 0.659
202112 -0.156 106.600 -0.176
202203 0.642 109.900 0.702
202206 0.631 113.600 0.668
202209 0.593 116.400 0.612
202212 0.028 115.900 0.029
202303 0.745 117.300 0.763
202306 0.643 116.400 0.664
202309 0.906 117.400 0.928
202312 -0.206 116.700 -0.212
202403 0.159 118.400 0.161
202406 1.118 118.500 1.134
202409 0.943 118.900 0.953
202412 -0.128 118.900 -0.129
202503 0.302 120.200 0.302

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk AS  (XTER:NOV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novo Nordisk AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.